EFFICIENCY OF FLUMEQUINE BIOENCAPSULATION IN ARTEMIA NAUPLII TO TREAT OEROCHROMUS NILUTICUS FRY INFECTED WITH AEROMONUS HYDROPHILLA

EFFICIENCY OF FLUMEQUINE BIOENCAPSULATION IN ARTEMIA NAUPLII TO TREAT OEROCHROMUS NILUTICUS FRY INFECTED WITH AEROMONUS HYDROPHILLA

Ahmed M. Abdel-Wahab

Fish Health and Management Department, Central Laboratory for Aquaculture Research, Agricultural Research Center, Egypt.

Abstract

Bioencapsulated of flumequine by Artemia nauplii was evaluated as a function of its concentration in the enrichment medium and of the duration of the enrichment period. An emulsion containing 20, 30 and 40% (w/w) flumequine (30, 45 and 60 mg flumequine/ml of enrichment) was administered to nauplii for 4, 8, 12, 24 or 32 h. Increased uptake of flumequine (440.2 ±15.1 μg/g dry weight) and good survival rates of the nauplii were observed with the 30% emulsion and 24 h enrichment. Curve of the body tissue concentration
of Artemia nauplii–time showed half-life were found to be 0.9 ± 0.10 h and the terminal phase elimination half-life were found to be 12.3 ± 6.90 h. In the efficacy trial the cumulative mortalities in groups treated with bioencapsulation treatments appeared significantly reduced amounting to 20 ± 2.90%, 19± 2.80%, and 22± 3.70% with groups taken 40%, 30% and 20% flumequine respectively. Mean cumulative mortality in unmedicated groups reached 91.80 ± 4.40% post challenge. Flumequine concentration was 65.40 ±6.80 μg/g in tilapia fry
after a 5-day oral treatment with medicated nauplii. It could be concluded that flumequine appears effective in treating of Aeromonus hydrophilla in Oerochromus niluticus fry. The best level of flumequine concentration was 30 (w/w).

Key words: Flumequine, Artemia, O. niluticus
fry.